December has been a big month for CRISPR Therapeutics (CRSP -9.01%). On Dec. 8, the Food and Drug Administration (FDA) granted approval for CRISPR's gene-editing therapy, Casgevy, as a treatment for sickle cell disease. It was a monumental decision as it also marked the first approval for a therapy utilizing the CRISPR/Cas9 gene-editing technology.Despite this positive news, shares of CRISPR Therapeutics have stalled in December. In fact, the stock is down since the news of the approval, and month to date i ...

"The thrill of victory and the agony of defeat."That phrase became well-known years ago thanks to sportscaster Jim McKay. And it pretty much sums up the different trajectories for CRISPR Therapeutics (CRSP -9.01%) and Pfizer (PFE -1.88%) in 2023. CRISPR Therapeutics has enjoyed the thrill of victory, while Pfizer has experienced the agony of defeat.But which of these two biopharmaceutical stocks is the better pick for a new bull market? Motley Fool contributors Adria Cimino and Keith Speights make the argum ...

Not applicable. Item 4. Mine Safety Disclosures. Not applicable. Item 5. Other Information. On September 7, 2023, Dr. Phuong Khanh Morrow, our Chief Medical Officer, adopted a trading arrangement intended to satisfy the affirmative defense conditions of Securities Exchange Act Rule 10b5-1(c) (a "Rule 10b5-1 trading arrangement") with respect to the sale of up to an aggregate of 94,699 common shares of the Company pursuant to the terms of such trading plan, inclusive of common shares that will be mandated to ...

CRISPR Therapeutics AG (NASDAQ:CRSP) Citi's 18th Annual BioPharma Conference Call September 6, 2023 11:20 AM ET Company Participants Sam Kulkarni - CEO Conference Call Participants Yigal Nochomovitz - Citigroup Yigal Nochomovitz We can get started. I'm Yigal Nochomovitz, I'm one of the biotech analysts at Citi. Next session is with the CEO of CRISPR, Sam Kulkarni. I cover CRISPR, I think, since the very beginning, since the IPO. So Sam, welcome. Thanks for doing this. Appreciate it. Sam Kulkarni Thanks fo ...

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 For the transition period from to . Switzerland Not Applicable (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) Accelerated filer☐ ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standard ...

CRISPR Therapeutics AG (NASDAQ:CRSP) JMP Securities Life Sciences Conference May 15, 2023 11:30 AM ET Company Participants Sam Kulkarni - CEO Conference Call Participants Silvan Türkcan - JMP Securities Silvan Türkcan Thanks. Welcome back. My name is Silvan Türkcan, a senior analyst for JMP Securities. I cover precision medicines. It’s my pleasure to host Sam Kulkarni, CEO of CRISPR Therapeutics. Thanks for joining us today. Sam Kulkarni Thank you, Silvan, for having us. Question-and-Answer Session Q - Silv ...

CRISPR Therapeutics AG (NASDAQ:CRSP) Bank of America Securities 2023 Health Care Conference May 9, 2023 1:40 PM ET Company Participants Sam Kulkarni - CEO Conference Call Participants Geoff Meacham - Bank of America Geoff Meacham Welcome to the morning session of the BofA Healthcare Conference. I'm Geoff Meacham. I'm the senior biopharma analyst here at BofA. And we're thrilled to have CRISPR Therapeutics here. And speaking on behalf, we have Sam Kulkarni. Sam, welcome. Sam Kulkarni Thank you. Question-and- ...

Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or UNITED STATES SECURITIES AND EXCHANGE COMMISSION For the transition period from to . (State or other jurisdiction of incorporation or organization) Baarerstrasse 14 6300 Zug, Switzerland Not Applicable (Address of principal executive offices) (Zip Code) Switzerland Not Applicable (I.R.S. Employer Identification No.) +41 (0)41 561 32 77 (R ...

Jon Terrett Session Type: Drug Development Special Track Session Session Title: New Drugs on the Horizon: Part 1 Employee of: CRISPR Therapeutics Stockholder in: CRISPR Therapeutics CRISPR THERAPEUTICS® standard character mark and design logo, CTX001™, CTX110®, CTX112™, CTX121™, CTX130™, CTX131™, CTX310™, CTX320™, CTX330™, COBALT™, VCTX210™, VCTX211™ and VCTX212™ are trademarks and registered trademarks of CRISPR Therapeutics AG. All other trademarks and registered trademarks are the property oftheir respec ...

CRISPR Therapeutics AG (NASDAQ:CRSP) Cowen 43rd Annual Healthcare Conference Call March 6, 2023 10:30 AM ET Company Participants Sam Kulkarni - Chief Executive Officer Conference Call Participants Tyler Van Buren - Cowen Tyler Van Buren Good morning, everyone. Tyler Van Buren here senior biotech analyst at TD Cowen. Thank you very much for joining TD Cowen’s 43rd Annual Healthcare Conference. For next session, it’s a privilege to have CRISPR here and in particular, Sam Kulkarni, the CEO. Sam, thank you very ...